Charles Schwab Investment Management Inc. Purchases 22,558 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Charles Schwab Investment Management Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 620,616 shares of the biopharmaceutical company’s stock after purchasing an additional 22,558 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $545,081,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Meyer Handelman Co. grew its position in Regeneron Pharmaceuticals by 11.4% during the third quarter. Meyer Handelman Co. now owns 4,235 shares of the biopharmaceutical company’s stock worth $3,485,000 after buying an additional 435 shares in the last quarter. Stifel Financial Corp grew its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the third quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock worth $25,537,000 after purchasing an additional 3,385 shares in the last quarter. LPL Financial LLC increased its position in shares of Regeneron Pharmaceuticals by 9.3% in the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock worth $33,522,000 after purchasing an additional 3,479 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 1,221 shares in the last quarter. Finally, Monetary Management Group Inc. grew its stake in Regeneron Pharmaceuticals by 4.8% in the 3rd quarter. Monetary Management Group Inc. now owns 1,095 shares of the biopharmaceutical company’s stock worth $901,000 after buying an additional 50 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, EVP Joseph J. Larosa sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at approximately $36,615,850. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total transaction of $950,000.00. Following the completion of the transaction, the executive vice president now owns 38,543 shares in the company, valued at approximately $36,615,850. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,095 shares of company stock worth $8,729,766. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.2 %

REGN traded up $11.33 on Tuesday, hitting $969.97. The company had a trading volume of 362,317 shares, compared to its average volume of 496,674. The stock has a fifty day simple moving average of $942.67 and a 200-day simple moving average of $899.44. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The firm has a market capitalization of $106.46 billion, a P/E ratio of 28.65, a P/E/G ratio of 2.74 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the company posted $10.96 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Bank of America raised their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. Finally, Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $981.71.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.